CN113243332B - Preparation and application of extensive brain area neuron tree sudden-breeding obstacle animal model - Google Patents
Preparation and application of extensive brain area neuron tree sudden-breeding obstacle animal model Download PDFInfo
- Publication number
- CN113243332B CN113243332B CN202010082845.5A CN202010082845A CN113243332B CN 113243332 B CN113243332 B CN 113243332B CN 202010082845 A CN202010082845 A CN 202010082845A CN 113243332 B CN113243332 B CN 113243332B
- Authority
- CN
- China
- Prior art keywords
- neuronal
- tree
- sudden
- disorder
- brain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004556 brain Anatomy 0.000 title claims abstract description 84
- 238000010171 animal model Methods 0.000 title claims abstract description 40
- 210000002569 neuron Anatomy 0.000 title claims abstract description 40
- 238000009395 breeding Methods 0.000 title abstract description 6
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 230000001537 neural effect Effects 0.000 claims abstract description 66
- 206010021143 Hypoxia Diseases 0.000 claims abstract description 50
- 230000007954 hypoxia Effects 0.000 claims abstract description 42
- 208000037824 growth disorder Diseases 0.000 claims abstract description 24
- 238000012360 testing method Methods 0.000 claims abstract description 21
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000001301 oxygen Substances 0.000 claims abstract description 19
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 19
- 230000007423 decrease Effects 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 238000012216 screening Methods 0.000 claims abstract description 8
- 210000001787 dendrite Anatomy 0.000 claims description 36
- 210000003520 dendritic spine Anatomy 0.000 claims description 34
- 230000002829 reductive effect Effects 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 14
- 238000011161 development Methods 0.000 claims description 13
- 230000018109 developmental process Effects 0.000 claims description 13
- 238000009826 distribution Methods 0.000 claims description 13
- 230000024573 dendritic spine development Effects 0.000 claims description 10
- 206010012559 Developmental delay Diseases 0.000 claims description 9
- 230000008859 change Effects 0.000 claims description 9
- 230000001766 physiological effect Effects 0.000 claims description 9
- 230000009467 reduction Effects 0.000 claims description 9
- 229940124606 potential therapeutic agent Drugs 0.000 claims description 7
- 210000000225 synapse Anatomy 0.000 claims description 7
- 241000283984 Rodentia Species 0.000 claims description 4
- 230000009984 peri-natal effect Effects 0.000 claims description 4
- 241000282693 Cercopithecidae Species 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 241000288906 Primates Species 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 208000010515 dystocia Diseases 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 7
- 206010000210 abortion Diseases 0.000 abstract 1
- 231100000176 abortion Toxicity 0.000 abstract 1
- 230000001488 breeding effect Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 27
- 230000006378 damage Effects 0.000 description 20
- 241000700159 Rattus Species 0.000 description 19
- 208000014674 injury Diseases 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- 208000027418 Wounds and injury Diseases 0.000 description 14
- 230000000971 hippocampal effect Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 10
- 230000000946 synaptic effect Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 7
- 210000001947 dentate gyrus Anatomy 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000001146 hypoxic effect Effects 0.000 description 7
- 230000006735 deficit Effects 0.000 description 6
- 230000003925 brain function Effects 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000002503 granulosa cell Anatomy 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000002025 microglial effect Effects 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000004641 brain development Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- 210000004295 hippocampal neuron Anatomy 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000004904 shortening Methods 0.000 description 3
- 230000006886 spatial memory Effects 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 230000031836 visual learning Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000002381 Brain Hypoxia Diseases 0.000 description 2
- 208000012239 Developmental disease Diseases 0.000 description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 230000009524 hypoxic brain injury Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000020796 long term synaptic depression Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 210000003538 post-synaptic density Anatomy 0.000 description 2
- 108010092804 postsynaptic density proteins Proteins 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 238000004804 winding Methods 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000007204 Brain death Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010048964 Carotid artery occlusion Diseases 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102100037249 Egl nine homolog 1 Human genes 0.000 description 1
- 101710111663 Egl nine homolog 1 Proteins 0.000 description 1
- 206010016855 Foetal distress syndrome Diseases 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- 206010028923 Neonatal asphyxia Diseases 0.000 description 1
- 206010050081 Neonatal hypoxia Diseases 0.000 description 1
- 102000050267 Neurotensin Human genes 0.000 description 1
- 101800001814 Neurotensin Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010046797 Uterine ischaemia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 208000009973 brain hypoxia - ischemia Diseases 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000021617 central nervous system development Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000004914 glial activation Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 210000001879 hippocampal ca1 region Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011173 large scale experimental method Methods 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000036997 mental performance Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002052 molecular layer Substances 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000008062 neuronal firing Effects 0.000 description 1
- 230000007121 neuropathological change Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/35—Animals modified by environmental factors, e.g. temperature, O2
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/106—Primate
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/107—Rabbit
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to preparation and application of a neuronal tree sudden-breeding obstacle animal model in a wide brain area. Specifically, the invention provides a preparation method of a non-human mammal model for treating sudden abortion of a neuron tree in a wide brain region, which comprises the following steps: exposing the non-human mammal to hypoxia conditions for 30-40 minutes to obtain an animal model of a wide range of neuronal tree sudden growth disorder in the brain region, wherein the oxygen concentration (volume ratio) decreases from 10-20% to 1-5%. The animal model of the invention can be used for researching the burst breeding disorder of the neuron tree in the wide brain area, and can be used for screening and testing specific medicines.
Description
Technical Field
The invention relates to the technical field of biology, in particular to preparation and application of an animal model for treating sudden-breeding disorder of a neuron tree in a wide brain area.
Background
Hypoxia/ischemic (H/I) injury is one of the main causes of brain functional deficits at all ages, and has been widely studied in both clinical and experimental animal studies, including etiology, neuropathogenesis, and pharmacological intervention. More and more studies have shown that H/I may adversely affect brain development in rodents.
Most current animal models of hypoxic brain injury are:
1. blocking arterial vessel + hypoxia-cerebral ischemia hypoxia model: disadvantages: anesthesia has neuroprotective effect; surgery itself has trauma; large infarct variation and instability; the model is troublesome to manufacture and small in batch; the success rate is low; the manufacturing period is long.
2. Middle cerebral artery occlusion model: this model, which is often used in adult mice, is only a model of cerebral ischemia or cerebral ischemia reperfusion injury, and has no hypoxia factor; is more suitable for clinical cerebral ischemia diseases and is a focal lesion model. Is not suitable for the simulation of ischemic and anoxic encephalopathy of newborns.
3. The method for clamping the air pipe comprises the following steps: the disadvantages are: the effects of anesthetic drugs on nerves; trauma caused by the operation itself; the technical requirement is high, and the period is long; the batch is small; since mice used are generally older (too little surgery difficult), they have poor consistency of pathological changes.
4. Establishing an intrauterine hypoxia model: disadvantages: data effects of anesthetic drugs; the operation itself is wounded; the surgical technical requirements are high; the consumption of surgical consumables is high; the period is long, and the batch is small; large difference and poor uniformity.
Therefore, there is an urgent need in the art to develop a new hypoxic brain injury animal model that can be used as a powerful tool for studying the pathogenesis of neuronal tree outbreak disorders in the wide brain area and for new drug screening.
Disclosure of Invention
The invention aims to provide an animal model which can be used as a powerful tool for researching pathogenesis of neuronal tree sudden growth disorder in a wide brain area and screening new medicines.
The first aspect of the invention provides a method for preparing a non-human mammal model for treating sudden dystocia of a neuronal tree in a wide brain region, comprising the following steps:
exposing the non-human mammal to hypoxia for 30-40 minutes, thereby obtaining an animal model of the neuronal tree sudden-growth disorder in the wide brain region,
wherein the oxygen concentration (volume ratio) is reduced from 10-20% to 1-5% under the low oxygen condition.
In another preferred embodiment, the extensive brain region neuronal tree sudden-growth disorder comprises an extensive brain region neuronal dendritic spine development disorder.
In another preferred embodiment, the non-human mammal is a rodent or primate, preferably comprising mice, rats, rabbits and/or monkeys.
In another preferred embodiment, the non-human mammal is a neonatal non-human mammal, preferably a neonatal non-human mammal (such as a rodent) within 24 hours of birth or a neonatal non-human mammal such as a primate at a perinatal period.
In another preferred embodiment, the inert gas is added under low oxygen conditions to reduce the oxygen concentration.
In another preferred embodiment, the inert gas is selected from the group consisting of: nitrogen, helium, or a combination thereof.
In another preferred embodiment, the extensive brain region neuronal tree sudden-growth disorder animal model has one or more characteristics selected from the group consisting of:
(t 1) no significant changes in brain morphology and brain size;
(t 2) no significant effect on systemic development of the animal;
(t 3) no significant effect on body weight of animals;
(t 4) no significant changes in the animal's general physiological activities including diet, excretion, respiration, heart rate, blood pressure, visual and auditory, pain and warmth, motor ability, reflex ability, etc.;
(t 5) structure under neuronal light mirror: the morphology, size, polarity, arrangement, number, density and distribution of the neurons are not changed significantly;
(t 6) microglial cells have no significant changes in the morphology, size, shape, distribution, number, density, etc. of their cell bodies and their projections;
(t 7) the synaptic physiological activity is significantly reduced;
(t 8) the morphology, size, number, density of the neuronal dendrites and dendritic spines is significantly reduced;
(t 9) the dendrite diameter and length of neurons decrease significantly;
(t 10) the number, distribution, area, etc. of synapses formed between neurons is significantly reduced;
(t 11) behavioral, emotional, cognitive functional deficits.
In another preferred embodiment, the synaptic physiological activity comprises: the mEPSCs amplitude and frequency.
In another preferred example, the behavioral, emotional, and cognitive functional deficits include reduced spatial learning and memory, reduced active exploring behavior, weaker fear of dangerous situations, and reduced natural mental performance of fear of bright areas.
In a second aspect, the invention provides the use of a non-human mammalian model prepared by a method according to the first aspect of the invention as an animal model for studying neuronal tree sudden growth disorders in the wide brain area.
In another preferred embodiment, the extensive brain region neuronal tree sudden-growth disorder comprises an extensive brain region neuronal dendritic spine development disorder.
In a third aspect, the invention provides the use of a non-human mammalian model prepared by the method of the first aspect of the invention for screening or identifying substances (therapeutic agents) which reduce or treat neuronal tree sudden growth disorders in the broad brain region.
In another preferred embodiment, the extensive brain region neuronal tree sudden-growth disorder comprises an extensive brain region neuronal dendritic spine development disorder.
In a fourth aspect, the invention provides a method of screening or identifying a potential therapeutic agent for treating or alleviating a neuronal tree emergency disorder in a broad brain region, comprising the steps of:
(a) In a test group, administering a test compound to a non-human mammalian model prepared by the method of the first aspect of the invention in the presence of the test compound, and detecting the severity Q1 of a neuronal tree burst disorder in the brain region of the animal model in the test group; and detecting the severity of neuronal tree burst disorder in the extensive brain area of the animal model in a control group without the test compound administered and under otherwise identical conditions Q2;
(b) Comparing the severity Q1 and severity Q2 detected in the previous step to determine whether the test compound is a potential therapeutic agent for treating or alleviating neuronal tree emergency disorders in the extensive brain area;
wherein a test compound is indicated as a potential therapeutic agent for treating or alleviating a broad brain area neuronal tree sudden growth disorder if the severity Q1 is significantly lower than the severity Q2 or if the severity of the broad brain area neuronal tree sudden growth disorder is reduced in an animal model to which the test compound is administered.
In another preferred embodiment, said detecting the severity of a neuronal tree sudden-breeding disorder in the brain region comprises detecting a change in one or more indicators selected from the group consisting of: sudden electric shock physiological activity; the shape, size, number, distribution and density of the spines of the nerve cells dendrites and dendritic spines in each brain region; the dendrite diameter, length, number of neurons; the development status of the distribution of the structures formed by the brain area synapses; behavior, emotion, cognitive function.
In another preferred embodiment, the decrease in severity of the wide brain area neuronal tree sudden growth disorder is manifested as: the degree of decrease in the physiological activity of the sudden electric shock is reduced; the density, size, number and degree of density decrease of the neuron dendritic spines are reduced; a reduction in the dendrite diameter, length, number of neurons; the extent of development of the distribution of the brain region processes and the structures they constitute is reduced; and/or reduced levels of behavioral, emotional, and cognitive deficits.
In another preferred embodiment, the "significantly lower" means that the test group with biological replicates has a lower severity Q1 after administration of the test compound than the control group with biological replicates has a severity Q2 after administration of the test compound, and has a P-value of less than 0.05 upon t-test.
In another preferred embodiment, the term "significantly lower" means that the ratio of severity Q1/severity Q2 is 1/2 or less, preferably 1/3 or less, more preferably 1/4 or less.
In another preferred embodiment, the method is non-diagnostic and non-therapeutic.
In another preferred embodiment, the method comprises the step of (c) administering the potential therapeutic agent screened or identified in step (b) to a non-human mammalian model prepared by the method of the first aspect of the invention, thereby determining its effect on the severity of neuronal tree burst disorder in the extensive brain region of said animal model.
In a fifth aspect the invention provides a non-human mammalian model prepared by the method of the first aspect of the invention.
It is understood that within the scope of the present invention, the above-described technical features of the present invention and technical features specifically described below (e.g., in the examples) may be combined with each other to constitute new or preferred technical solutions. And are limited to a space, and are not described in detail herein.
Drawings
Figure 1 shows that the present model animals did not cause substantial significant changes after being subjected to hypoxia challenge. Wherein A: no change in the appearance of the brain was found; b: no change in body weight was caused.
Figure 2 shows that the neuronal electrophysiological activity of the model mice was significantly affected after experiencing hypoxia stroke. Wherein, A-C: in vitro electrophysiology showed a decrease in synaptic activity between brain neurons after hypoxia; D-F: changes in electrophysiological function in the hippocampal brain region after hypoxia are shown to be inhibited over a long period of time (LYD).
Fig. 3 shows that no significant changes in neuronal morphology, size, arrangement, number, distribution, density were observed under the brain mirror after hypoxia (a-J).
Figure 4 shows that no significant changes in microglial morphology, size, arrangement, number, distribution, density were observed under the brain microscope after hypoxia (a-F).
Figure 5 shows that the dendritic diameter, size, number, density of neurons in the hippocampal region (B) decreased significantly in early stages (7 days post-natal) after hypoxia compared to normal mice (a); this difference is more pronounced in adulthood (C, D)
FIG. 6 shows that other brain regions besides the hippocampus, such as Dentate Gyrus (DG), the dendrites and dendritic spines of nerve cells also see significant changes (A-F) in the reduction of dendrite diameter, shortening of dendrite length, and reduction of dendritic spine density due to hypoxia; in the CA3 region, the volume of the region formed by the aggregation of synapses formed by the neuronal dendrites is reduced (G-I).
Fig. 7 shows that neurons cultured in a hypoxic environment, which give significantly reduced length of dendrites, were significantly reduced on day 7 (a, B) and significantly different on day 7 (C, D) by means of in vitro cell culture.
FIG. 8 shows that after adulthood, mice that had been subjected to hypoxia strikes during the neonatal period, from the change in escape latency, reflected a significant decline in spatial learning (A); after withdrawal from the platform, the movement trace (C) of the rat reflects the same significant decline in spatial memory (B, D).
Detailed Description
The inventor has conducted extensive and intensive studies, and has unexpectedly found that an animal model of a wide brain region neuronal tree sudden-growth disorder can be obtained by exposing a non-human mammal to a low oxygen condition in which the oxygen concentration (volume ratio) is reduced from 10 to 20% to 1 to 5% for 30 to 40 minutes. The present invention has been completed on the basis of this finding.
Burst dysgenesis of neuronal tree in extensive brain area
In the present invention, a relatively mild hypoxic condition (i.e., a mammal exposed to an oxygen concentration environment of varying concentration, e.g., a reduced oxygen concentration (volume ratio) from 10-20% to 1-5%) is established, resulting in significant developmental disorders of neuronal dendrites and their dendritic spines, which result in sustained structural damage that can lead to impairment of learning and memory or even other cognitive activities.
Animal model
In the present invention, a very effective non-human mammalian model of a wide brain area neuronal tree sudden growth disorder is provided.
In the present invention, examples of non-human mammals include (but are not limited to): mice, rats, rabbits, monkeys, etc., more preferably rats and mice.
The animal model of the invention is prepared by the following method:
exposing the non-human mammal to hypoxia for 30-40 minutes, thereby obtaining an animal model of the neuronal tree sudden-growth disorder in the wide brain region,
wherein the oxygen concentration (volume ratio) is reduced from 10-20% to 1-5% under the low oxygen condition.
The animal model obtained by the method is fertile and has normal development.
Candidate drugs or therapeutic agents
In the present invention, there is also provided a method for screening candidate drugs or therapeutic agents for treating a neuronal tree emergency disorder in a wide brain area using the animal model of the present invention.
In the present invention, a candidate drug or therapeutic agent refers to a substance known to have a certain pharmacological activity or being tested for a potential to have a certain pharmacological activity, including but not limited to nucleic acids, proteins, chemically synthesized small or large molecular compounds, cells, etc. The drug candidate or therapeutic agent may be administered orally, intravenously, intraperitoneally, subcutaneously, intraspinal, or by direct intracerebral injection.
The main advantages of the invention include:
1. the experimental conditions are simple.
2. The manufacturing process is simple.
3. The intervention treatment factors are single. Only one condition of hypoxia is given, and no operation, administration and the like are performed on animal bodies.
4. The model is uniform. The individual difference is small, the birth time of the newborn is easy to grasp, and the newborn is hardly interfered by the outside after birth.
5. The index is clear. The morphological, electrophysiological and brain function change indexes are definite, obvious and stable.
6. The lesion point is focused. The injury sites are concentrated in the dendritic spines, and are clear and focused. Cell body, cell shape, polar orientation, arrangement, size, number, density, etc. are not affected.
7. The function of the damage point is critical. The sites of model damage are gathered on dendritic spines, the dendritic spines are key nodes of the neuron connection of the brain forming network, are main channels for transmitting signals, which are mutually influenced, among the neurons, are key points of the signal transmission efficiency of the central nervous system network system, and are main structural bases of brain functions.
8. The damage mechanism of the dendritic spines is clear. Hypoxia causes a disturbance of neuronal metabolism, affects energy supply, causes dysplasia of the dendritic spine, and the developmental deformity of the dendritic spine exists for life and accompanies a decrease in brain function.
9. The success rate is high. The model was stable, 100% successful.
10. Can be produced in batch. Meanwhile, a large number of homogeneous models are manufactured, so that large-scale experiments can be conveniently carried out.
11. Can be used as a powerful tool for researching pathogenesis of the neuronal tree sudden-growth disorder in the wide brain area and screening new drugs.
12. The animal model of the invention has stable phenotype.
13. The animal model obtained by the method is fertile, and the general structure of the organism is normal.
14. The animal model of the invention can be used to study the role and mechanism of TSH in early brain neuron dendritic spine development.
15. The animal model of the invention can be used for exploring, researching, developing and verifying potential drugs or means and methods to intervene TSH injury and block dendritic spine development injury; improving development disorder of dendritic spines.
16. The animal model of the invention can be used for researching the functional change of the nervous system operation and the operation mechanism thereof under the pathological condition of dendritic spine development disorder.
17. The animal model of the invention is used as a nervous system model reference for mental disorder, and is used for study and memory comparison reference under other nervous system pathological modes (such as senile dementia).
The invention will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. The experimental procedure, which does not address the specific conditions in the examples below, is generally followed by routine conditions, such as, for example, sambrook et al, molecular cloning: conditions described in the laboratory Manual (New York: cold Spring Harbor Laboratory Press, 1989) or as recommended by the manufacturer. Percentages and parts are weight percentages and parts unless otherwise indicated.
Unless otherwise indicated, the materials used in the examples were all commercially available products.
Manufacturing process
1. Pregnant mice were kept in an animal room with 12 hours of light and a 12 hour dark cycle, which allowed free access to food and water until they were born.
2. After birth and 6 hours of maternal feeding, these neonates were randomly divided into two groups.
3. In TSH treatment, the neonates were first placed in a hypoxic chamber with an oxygen concentration of 15% and gradually adjusted to 3% by N2 over 30 minutes at 30 ℃. Thereafter, the oxygen concentration was maintained at 3%, and the neonate rat was left in the tank for another 5 minutes. Thus, the total hypoxic injury lasted 35 minutes. For the normoxic group, the neonates were placed in the box for 35 minutes with a normoxic concentration of 21%.
4. After the hypoxia process is completed, all the neonatal mice are returned to the cage, and the neonatal mice are the same as the mother mice.
Desired preparation conditions
1. An oxygen control cell incubator, or a special animal raising box
2. If no special equipment is provided, a common cell incubator can be used, with the addition of a closed box capable of controlling the oxygen concentration.
Detecting index results
1. The survival rate is high: after TSH treatment, the brain general morphology and body weight of 50 newborn mice are recovered to be normal, and the total survival is achieved.
2. The hypoxia systemic reaction is obvious: at the end of hypoxia treatment, the whole body color of the neonate mice was darker than the normal control group and recovered soon after the end of hypoxia treatment.
3. Brain morphology is unchanged: the brains of young rats that received TSH and normoxic treatment within 5 and 7 days, respectively, were also carefully compared by the investigator. There were no significant differences in brain morphology and brain size between the hypoxia-treated group and the normoxic group (fig. 1A).
4. Body weight is unchanged: the growth rates of hypoxia-treated and normoxic-treated neonates were similar (n=8, p > 0.05) weights (fig. 1B). These observations indicate that TSH has no significant effect on the overall development of the animal.
5. The physiological activity of the sudden electric shock is reduced: to explore whether TSH effects on neurological function, spontaneous synaptic activity was recorded using patch clamp, hippocampal slices TSH (n=27 neurons) and normoxica treated rat neurons (n=31), i.e. glutamate receptor mediated mini excitatory postsynaptic currents (mEPSCs) were recorded in CA1 neurons. TSH treated rats had a mpescs amplitude (pA) of 15.18±0.43 (pA), and the difference was statistically significant compared to 17.70±0.28 (pA) of the control group (p < 0.001) (fig. 2A and 2B). TSH treated rats had a frequency of 3.98±0.55 (Hz) and were also significantly reduced (figures 2A and 2C) compared to 6.35±0.49 (Hz) for the control group (p < 0.01). In addition, in vivo hippocampal CA1 synaptic activity recordings showed that TSH injured (n=23 neurons) animals had a neuronal firing rate of 8.74±0.63 (spike/s), significantly higher than 5.06±0.45 (spike/s), p <0.001 (fig. 2D) for the normal motor control group (n=25 neurons). Since both amplitude and frequency of mpescs were significantly reduced in TSH rat hippocampal CA1, we suspected if the reduction of basal synaptic transmission also affected synaptic plasticity of hippocampal brain slices. The extracellular long-term potential (LTP) of the hippocampal CA1 region was the same as that of the normal control group in the TSH treated group (fig. 2E). However, hypoxia significantly inhibited long-term depression (LTD) (fig. 2F). These results indicate that neuronal synaptic activity is disrupted after TSH injury.
6. The morphology and the optical lens structure of the neuron are unchanged: TSH does not cause structural changes in brain nerve cells. We examined whether the number of hippocampal neurons was altered following TSH injury. Nile staining was shown (FIG. 3, A-J). Observations of hippocampal CA1 neuron density TSH and normal rats at P5, P7, P21 and P90 are shown in table 1. These observations support that no significant cell loss or overall structural changes in hippocampal CA1 occurred at different developmental ages after TSH injury.
TABLE 1
7. Microglial cells were not activated. TSH does not induce brain activation of microglia. Observation of the morphology, number, distribution, density, etc. of hippocampal CA1 microglial cells in rats with hypoxia, compared to normal (FIG. 4, A, B, C), showed no apparent activation (FIG. 4, D, E, F).
Tsh results in a decrease in density of hippocampal neurons dendritic spines. Structural details of granulosa cells in hippocampal CA1 neurons dendrites, dendritic spines and brain region DG were examined at day 7 and day 90 after TSH treatment, respectively. Normal rat neurons had dendritic spines distributed in clusters along dendrites, and the dendritic spines TSH of animals were significantly reduced after hypoxia, sparsely distributed, and only a small amount distributed along dendrites (fig. 5). On day 7 post-natal, the density of dendritic spines per 10um,8.5±4.0, was significant of, <0.001 compared to the normal control group 15.1±2.9/10m (fig. 5a, b). 3 months after TSH injury, the reduction in dendritic spine density was 14.0.+ -. 3.9/10um, while the normal sports group animals had a spine density of 23.7.+ -. 4.6/10um (< 0.05) (FIGS. 5C, D).
9. The dendrite diameter of neurons decreases. In addition to dendritic spine density, we examined neuronal dendrites of hippocampal CA1, especially secondary branches, on days 7 and 90 after TSH treatment or normoxic treatment. At P7, the mean dendrite diameter of TSH animals was approximately the same as that of the normal control group. However, the diameter of the secondary branches of the neuronal dendrites of TSH treated animals was statistically smaller than that of normoxic control. Similar results were also observed 90 days after hypoxia and normoxic treatment (fig. 5 and table 2).
TABLE 2
Sh causes abnormal development of DG and CA3 regions. Observations of the dentate gyrus of the hippocampus further confirmed the reduced density of dendritic spines and the secondary branch attenuation of dendrites in hippocampus CA1 (fig. 6A, 6B, 6C). At P90, the DG granulosa cells of the TSH treated animals had a dendritic spine density of 7.03.+ -. 0.53/10um, which was lower than 14.8.+ -. 0.60/10um, P <0.0001 for the normoxic control group (FIG. 6D). The length of the TSH group dendrite is obviously shortened compared with that of the control group. 90 days after TSH treatment, the dendritic diameter of the animal dentate gyrate granulosa cells was 0.893.+ -. 0.064m, significantly greater than 0.628.+ -. 0.046m, p <0.05 for the normal control group (FIG. 6E). Dendritic shrinkage length of the 90d animals hippocampal DG molecular layer (IML) granulosa cells after TSH treatment was 15.35±1.75m, significantly higher than Yu Chang oxygen control group 7.04±1.02m, p <0.001 (fig. 6F). Finally, brain sections of animals stained for tim at 90 days of age showed a significant decrease in tim positive particles in the CA3 region of the hippocampus of TSH group compared to the control group (fig. 6G and 6H). The mean transparent layer width of hippocampal CA3 in TSH-injured group was 117.3±4.63um, significantly reduced compared to 146.0±5.82um in normal control group, p <0.005 (fig. 6I).
11. Hypoxia nerve cell culture neurons are impaired in dendrite growth. In vitro experiments are carried out by using a cell culture method, and the influence of hypoxia on the growth and development of the neuron dendrites is further verified. The experimental results showed that the growth of the neuronal dendrites was slow, the protrusion was shortened, and the branching was reduced under hypoxia (5% o 2) conditions for 7 days continuously, starting from the first day; and persisted, and on day 7 of the observation period, neuronal morphology in normoxic conditions was compared (fig. 7C), with a significant decrease in both hypoxic neuronal dendrite length and density (fig. 7D).
Tsh can lead to long-term cognitive dysfunction. Morris water maze experiments were performed on 3 months old TSH and normoxic treated rats. In spatial navigational training over 4.5 days, rats in the control group and the hypoxic group showed similar improvement in the first 6 exercises and all animals had a shortened latency in finding the platform. However, from training results 7, 8 and 9, there was a significant difference between TSH injury and normal hypoxia treated animals. The incubation periods of the TSH group rats were 21.6± 3.71,16.6 ± 1.79,20.4 ±3.86, respectively, significantly longer than 12.1± 1.72,7.99 ± 1.03,8.07 ±0.96 of the control group, respectively (p < 0.05) (fig. 8A). After 9 training trials, all rats were subjected to space exploration testing without MWM platform. The trace of swimming was recorded digitally. The number of platform website traversals of TSH, on day 5, 9.43+ -1.29 and 2.00+ -1.15, was 16.75+ -2.18,6.29 + -2.36 for normal mice, respectively, with significant differences (p <0.05, FIG. 8B). In addition, TSH animals swim a distance of 26475±2412mm in the quadrant where the platform was located, p <0.05 compared to control 35862±3371mm (fig. 8C and 8D). These results strongly suggest that neonatal rat TSH injury can lead to brain developmental disorders, leading to brain functional deficits, including spatial learning and memory.
Discussion of the invention
Animal model study of TSH perinatal neonates. The brain is one of the most sensitive organs to hypoxia, which can lead to coma, epilepsy, cognitive dysfunction and other neurological dysfunction, and even brain death, over time. Neonatal hypoxia injury is generally thought to be due to umbilical cord cervical winding, head basin unlevel, birth incarceration, uterine ischemia, and neonatal asphyxia. Perinatal hypoxic ischemic brain injury causes higher mortality and chronic neurological morbidity in acute infants and children, often with sequelae. The invention discovers that TSH causes obvious pathological changes including dendritic thinning, shortening, dendritic spine density reduction, synaptic structure reduction and synaptic physiological function reduction of central nervous system neurons for the first time; furthermore, impaired cognitive function was observed in animals with TSH. The data of the present invention clearly demonstrate that TSH can cause significant neurotensin and dendritic toxicity in the neonatal as well as in the adult stage. Thus, the present invention provides a useful animal model for studying the effects and mechanisms of sublethal hypoxia on early brain development and for exploring potential intervention drugs or methods.
The study of the present invention shows that neonatal rats were given a short sublethal hypoxia for 35 minutes alone 6 hours after birth, unlike animal models previously used for hypoxia/ischemia studies. Animals born for 6 hours are used in the current study, which is more similar to clinical situations (umbilical cord neck winding, birth incarceration, uterine deformity, etc.) than many previous hypoxia/ischemia studies, wherein animals are used for about one day old, the shorter the time after birth, the smaller the individual variation coefficient of the animals after birth, and the better the uniformity of the nervous system among the animals. One single factor gradient hypoxia supply is the second difference between current studies and past animal models using carotid occlusion and hypoxia (two factors). Finally, the TSH injury group does not have obvious neuropathological changes, does not have neuron loss and glial activation, but has durable brain function defects observed, and is a model which is more suitable for simulating more common clinical moderate and mild ischemic anoxic encephalopathy. Because of its low severity of hypoxia, the condition is difficult to diagnose, lacks adequate care or treatment, and ultimately leads to severe brain developmental dysfunction. Thus, the present study provides an important animal model and useful data for clinical practice of transient sublethal hypoxia single injury.
TSH blocks spontaneous synaptic activity of neurons. Background activity of electroencephalogram (EEG) was found in very early premature infants and animals. In this study, TSH resulted in a decrease in amplitude and frequency of hippocampal CA1 neurons, mpescs, compared to the normal control group. TSH has a negative impact on neuronal dendrite development. In the present invention, the neuronal dendrite diameter of animals was significantly reduced after TSH treatment compared to the control group. The total length of dendrites of primary cultured hippocampal neurons after 5% oxygen treatment was also significantly lower than that of normal control group. These results indicate that damage to TSH induces dendritic toxicity, affecting the growth and development of neuronal dendrites. Hypoxia-induced energy deficit may affect cytoskeletal dynamics including actin and microtubules. Actin and MT are key to the development of conventional dendrites and are targets for many molecular pathways that control neuronal dendrite growth. During brain development, both actin and MT cytoskeletal structures change, producing neuronal projections. The present invention also finds that TSH damage reduces the density and development of dendritic spines. More than 95% of excitatory synapses on these neurons occur on dendritic spines, with each spiny head typically connected to form a synapse. The formation and plasticity of dendritic spines is important for brain function. Development of dendritic spines is controlled by oxygen sensor PHD2, targeting actin crosslinker Filamin-a, regulating synaptic density and neuronal activity within the network. Dendritic spine associated Rap-specific gdpase activator protein (SPAR) is a postsynaptic protein that forms a complex with postsynaptic density (PSD) -95, which is involved in regulating the morphogenesis of dendritic spine with N-methyl-D-aspartate receptors (NMDARs).
The structure and dynamics of dendritic spines reflect the strength of synapses, which are often severely affected in different brain diseases, including neurodegenerative and psychiatric diseases. Dendritic spines can undergo several types of transformations, from growth to collapse, from elongation to shortening, with very short spans of time that they undergo such dynamic morphological activities. The change of the number and morphology of dendritic spines occurs not only in pathological conditions such as excitotoxicity, but also in the normal central nervous system development, hormonal fluctuations and the response of neural activity in physiological environments.
All documents mentioned in this application are incorporated by reference as if each were individually incorporated by reference. Further, it will be appreciated that various changes and modifications may be made by those skilled in the art after reading the above teachings, and such equivalents are intended to fall within the scope of the claims appended hereto.
Claims (10)
1. A method for preparing a non-human mammal model for treating sudden dystocia of a neuron tree in a wide brain region, which is characterized by comprising the following steps:
exposing the non-human mammal to hypoxia for 30-40 minutes, thereby obtaining an animal model of the neuronal tree sudden-growth disorder in the wide brain region,
wherein the oxygen concentration volume ratio is reduced from 10-20% to 1-5% under the hypoxia condition, and the extensive brain region neuron tree sudden-growth disorder animal model has a plurality of characteristics selected from the group consisting of:
the physiological activity of the sudden electric shock is obviously reduced;
the morphology, size, number and density of the dendrites of the neurons and the dendrites are remarkably reduced;
the dendrite diameter and length of neurons decrease significantly;
the number, distribution, and area of synapses formed between neurons are significantly reduced, and the extensive brain region neuronal tree sudden growth disorder includes extensive brain region neuronal dendritic spine development disorder.
2. The method of claim 1, wherein the non-human mammal is a rodent or primate.
3. The method of claim 2, wherein the non-human mammal comprises a mouse, a rat, a rabbit, and/or a monkey.
4. The method of claim 1, wherein the non-human mammal is a neonatal non-human mammal.
5. The method of claim 4, wherein the non-human mammal is a neonatal non-human mammal within 24 hours of birth or a neonatal non-human mammal in the perinatal period.
6. Use of a non-human mammalian model prepared by the method of claim 1 as an animal model for studying a wide brain area neuronal tree sudden growth disorder, including a wide brain area neuronal dendritic spine development disorder.
7. Use of a non-human mammalian model prepared by the method of claim 1, for screening or identifying substances that reduce or treat a wide brain area neuronal tree emergency disorder, including a wide brain area neuronal dendritic spine development disorder.
8. A method of screening or identifying a potential therapeutic agent for treating or alleviating a neuronal tree emergency disorder in a broad brain region, comprising the steps of:
(a) In a test group, administering a test compound to a non-human mammalian model prepared by the method of claim 1 in the presence of the test compound, and detecting the severity Q1 of a neuronal tree burst disorder in the extensive brain area of said animal model in the test group; and detecting the severity of neuronal tree burst disorder in the extensive brain area of the animal model in a control group without the test compound administered and under otherwise identical conditions Q2;
(b) Comparing the severity Q1 and severity Q2 detected in the previous step to determine whether the test compound is a potential therapeutic agent for treating or alleviating neuronal tree emergency disorders in the extensive brain area;
wherein, if the severity Q1 is significantly lower than the severity Q2 or if the severity of a wide brain area neuronal tree sudden-growth disorder in an animal model to which a test compound is administered is reduced, the test compound is indicated to be a potential therapeutic agent for treating or alleviating a wide brain area neuronal tree sudden-growth disorder, including a wide brain area neuronal dendritic spine development disorder.
9. The method of claim 8, wherein detecting the severity of the extensive brain region neuronal tree sudden-growth disorder comprises detecting a change in a plurality of indicators selected from the group consisting of: sudden electric shock physiological activity; the shape, size, number, distribution and density of the spines of the nerve cells dendrites and dendritic spines in each brain region; the dendrite diameter, length, number of neurons; each brain region protrudes and develops in the distribution of its constituent structures.
10. The method of claim 8, wherein the decrease in severity of the extensive brain region neuronal tree sudden growth disorder is manifested by: the degree of decrease in the physiological activity of the sudden electric shock is reduced; the density, size, number and degree of density decrease of the neuron dendritic spines are reduced; a reduction in the dendrite diameter, length, number of neurons; and the extent of development of the distribution of the brain region processes and the structures they constitute is reduced.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010082845.5A CN113243332B (en) | 2020-02-07 | 2020-02-07 | Preparation and application of extensive brain area neuron tree sudden-breeding obstacle animal model |
PCT/CN2021/075854 WO2021155866A1 (en) | 2020-02-07 | 2021-02-07 | Preparation and application of animal model of neuronal dendritic dysplasia in extensive brain regions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010082845.5A CN113243332B (en) | 2020-02-07 | 2020-02-07 | Preparation and application of extensive brain area neuron tree sudden-breeding obstacle animal model |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113243332A CN113243332A (en) | 2021-08-13 |
CN113243332B true CN113243332B (en) | 2023-07-28 |
Family
ID=77200423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010082845.5A Active CN113243332B (en) | 2020-02-07 | 2020-02-07 | Preparation and application of extensive brain area neuron tree sudden-breeding obstacle animal model |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113243332B (en) |
WO (1) | WO2021155866A1 (en) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1521259A (en) * | 2003-01-30 | 2004-08-18 | 清华大学 | Drosophila disease model for screening anti-dementia drug and constructing method and application thereof |
CA2623839C (en) * | 2005-09-26 | 2013-12-17 | The Regents Of The University Of California | Estriol therapy for autoimmune and neurodegenerataive diseases and disorders |
GB2480413B (en) * | 2009-02-18 | 2014-12-24 | Univ Wayne State | Method for identifying a subpopulation of mammalian cells with distinctive ribosome translation profiles |
CN102037930A (en) * | 2010-08-27 | 2011-05-04 | 浙江大学 | Establishing method of PPHN (Persistent Pulmonary Hypertension of Newborn) animal model |
EP2653163A1 (en) * | 2012-04-19 | 2013-10-23 | Université de Liège | Estrogenic components for use in the treatment of neurological disorders |
WO2015013397A2 (en) * | 2013-07-25 | 2015-01-29 | Neuren Pharmaceuticals Limited | Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders |
CN103535322B (en) * | 2013-09-17 | 2016-03-30 | 中国人民解放军***总医院 | A kind of construction method of HACE animal model |
CN107753957B (en) * | 2016-08-23 | 2022-01-18 | 中国科学院上海药物研究所 | Establishing method and application of non-human mammal animal model for apoplexy or relevant diseases thereof |
EP3508207B1 (en) * | 2016-08-30 | 2021-08-11 | Niigata University | Cell preparations cultivated under low oxygen and sugar conditions, and their uses in therapy. |
-
2020
- 2020-02-07 CN CN202010082845.5A patent/CN113243332B/en active Active
-
2021
- 2021-02-07 WO PCT/CN2021/075854 patent/WO2021155866A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN113243332A (en) | 2021-08-13 |
WO2021155866A1 (en) | 2021-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bilimoria et al. | Microglia function during brain development: new insights from animal models | |
Allan et al. | A mouse model of prenatal ethanol exposure using a voluntary drinking paradigm | |
Fields | White matter in learning, cognition and psychiatric disorders | |
Ha et al. | Diabetes accelerates retinal ganglion cell dysfunction in mice lacking sigma receptor 1 | |
Deurveilher et al. | Microglia dynamics in sleep/wake states and in response to sleep loss | |
Le et al. | Early retinoic acid deprivation in developing zebrafish results in microphthalmia | |
Datta et al. | Identification of cholinergic and non-cholinergic neurons in the pons expressing phosphorylated cyclic adenosine monophosphate response element-binding protein as a function of rapid eye movement sleep | |
Royo et al. | Effects of n-3 polyunsaturated fatty acid supplementation on cognitive functions, electrocortical activity and neurogenesis in a non-human primate, the grey mouse lemur (Microcebus murinus) | |
Shi et al. | Mimicking partial to total placental insufficiency in a rabbit model of cerebral palsy | |
Trovato et al. | Modelling genetic mosaicism of neurodevelopmental disorders in vivo by a Cre-amplifying fluorescent reporter | |
Kabrita et al. | Development of the mouse suprachiasmatic nucleus: determination of time of cell origin and spatial arrangements within the nucleus | |
Rao et al. | Elucidating mechanisms of neuronal circuit formation in layer 4 of the somatosensory cortex via intravital imaging | |
Hoshino et al. | Ephrin‐A3 is required for tonotopic map precision and auditory functions in the mouse auditory brainstem | |
Wahlsten | Genetic and developmental defects of the mouse corpus callosum | |
CN113243332B (en) | Preparation and application of extensive brain area neuron tree sudden-breeding obstacle animal model | |
Tucker et al. | Sympathetic innervation alters growth and intrinsic heart rate of fetal rat atria maturing in oculo. | |
Chen et al. | Differential activation of limbic circuitry associated with chronic ethanol withdrawal in DBA/2J and C57BL/6J mice | |
Freedman et al. | Initial studies of embryonic transplants of human hippocampus and cerebral cortex derived from schizophrenic women | |
Pappas et al. | Ectopic noradrenergic hyperinnervation does not functionally compensate for neonatal forebrain acetylcholine lesion | |
Anegroaie et al. | Development of somatosensory‐evoked potentials in foetal sheep: effects of betamethasone | |
Tang et al. | Transient sublethal hypoxia in neonatal rats causes reduced dendritic spines, aberrant synaptic plasticity, and impairments in memory | |
Hegmann et al. | Gene differences influencing visual system function and behavior | |
Saad et al. | The Effect of Retinoic Acid on the Development of Neural Tube at Early Stages of Chicken Embryo | |
Stenstrom et al. | The Direction of response selectivity between conspecific and heterospecific auditory stimuli varies with response metric | |
Xiao et al. | Stabilizing axin leads to optic nerve hypoplasia in a mouse model of autism |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |